Prokaryotic expression of outer membrane protein A ( ompA) gene of Aeromonas hydrophila and its immunoprotection

郑宗林,郑曙明,DelbertM.GatlinIII,汪开毓
DOI: https://doi.org/10.3969/j.issn.1000-6907.2015.05.001
2015-01-01
Abstract:The expression of outer membrane protein A (OmpA) from Aeromonas hydrophila (PDK06) in Escherichia coli, the antigenicity and immunoprotection in Ictalurus punctatus were analyzed. According to ompA gene sequence published in GenBank (AF146597), no signal peptide primers were designed and the DNA fragment of about 1 000 bp was amplified by Polymerase Chain Reaction (PCR) from genomic DNA of A. hydrophila PDK06, isolated from disease I. punctatus. The se-quence was sub-cloned into pET-32a ( +) and the recombinant plasmid was named pET-32a ( +) -pompA which was further transferred into host bacteria E. coli BL21 (DE3) with IPTG induction for expression. The immune effect of the pompA with adjuvants ( FIA) against I. punctatus infected A. hydrophila were detected. The results showed the no signal peptide ompA gene of A. hydrophila was 960 bp in length, encoding a protein comprising 319 amino acids, of which the putative relative molecular mass was 53. 67 kDa. The FIA can improve the serum lysozyme activity, ACH50 activity and head kidney macrophage respiratory burst activity. The antibody level of the vaccinated fish without FIA were the highest at 4 weeks p. v. , while the antibody level of the vaccinated fish with FIA peaked at 5 weeks p. v. , which indicated FIA can significantly improve serum antibody levels of I. punctatus. The cumulative mortalities of the vaccinated fish were 93. 33%(PBS), 93. 33% (FIA), 50. 00% (pompA), and 13. 33% (FIA +pompA), respectively, which correspond to an RPS of 46. 43% and 85. 71% for pompA and FIA + pompA, respectively. The result of serum bactericidal activity sugges-ted that the survival rates of A. hydrophila of the vaccinated fish were significantly lower than the survival rate of the control, and the bacterial survival rate of the FIA+pompA vaccinated fish was the lowest. These indicated that pompA can be a sub-unit vaccine candidate vaccine, and FIA was a suitable adjuvant to enhanced the performance of pompA.
What problem does this paper attempt to address?